JORDAN JOURNAL OF BIOLOGICAL SCIENCES

Jordan Journal of Biological Sciences

Journal homepage: www.jjbsci.com

Amino acids and inborn errors of metabolism - A Comprehensive Review of Biochemistry, Pathophysiology, Clinical Features, and Therapeutic Advances

Smiti Pradhan.[1]

[1]Department of Bioinformatics, Bionome, Bengaluru, Karnataka 560043

To cite this article: Smiti Pradhan (2026) Amino acids and inborn errors of metabolism - A Comprehensive Review of Biochemistry, Pathophysiology, Clinical Features, and Therapeutic Advances; JJBS; 18:3, 55:66.

ABSTRACT
Amino acids serve as the fundamental building blocks of proteins and participate in a vast array of metabolic processes essential for human life. Inborn errors of metabolism (IEM) involving amino acid pathways represent a clinically important group of genetic disorders caused by enzyme deficiencies or transport defects that disrupt normal amino acid catabolism and biosynthesis. These disorders, though individually rare, collectively affect millions worldwide and account for significant morbidity, intellectual disability, and mortality if undetected or untreated. This comprehensive review explores the biochemistry of amino acid structure and classification, the enzymatic pathways governing their metabolism, and the molecular mechanisms underlying major inborn errors including phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, tyrosinemia, urea cycle disorders, organic acidemias, and disorders of sulfur-containing amino acids. We further discuss the pathophysiological consequences of metabolite accumulation, clinical manifestations, newborn screening approaches, and both established and emerging therapeutic strategies including dietary management, enzyme replacement therapy, pharmacological chaperones, substrate reduction therapy, and gene therapy. A thorough understanding of these conditions is vital for clinicians, biochemists, and genetic counselors involved in the diagnosis and management of affected individuals.

Keywords: Amino acids, inborn errors of metabolism, phenylketonuria, maple syrup urine disease, urea cycle disorders, newborn screening, enzyme deficiency, metabolic disorders, organic acidemia, homocystinuria

ARTICLE HISTORY

Received 10 Mar 2026
Revised 16 Mar 2026
Accepted 21 Mar 2026

1. INTRODUCTION

Amino acids constitute the fundamental molecular units from which all proteins are assembled, and they participate individually in numerous metabolic, signaling, and regulatory pathways. The human genome encodes over 20 standard amino acids that are incorporated into proteins via ribosomal translation, while non-protein amino acids serve as metabolic intermediates, neurotransmitters, and signaling molecules. The metabolism of amino acids involves intricate enzymatic networks operating primarily in the liver, kidney, muscle, and brain, and disturbances in these pathways—whether genetic or acquired—have profound biological consequences (Fernandez-Tejada et al., 2022).

Inborn errors of metabolism (IEM) represent a diverse group of inherited disorders in which specific enzymatic steps in metabolic pathways are deficient or absent due to pathogenic mutations in corresponding genes. First described by Sir Archibald Garrod in the early twentieth century, IEM were the earliest recognized examples of the biochemical basis of inherited disease. Garrod's observations on alkaptonuria, cystinuria, pentosuria, and albinism in the early 1900s established the 'one gene, one enzyme' concept decades before the molecular era (Garrod, 1909; Scriver et al., 2001). Among IEM, amino acid metabolism disorders occupy a central place due to their frequency, clinical severity, and biochemical complexity. Conditions such as phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, and urea cycle disorders can lead to irreversible neurological damage, intellectual disability, coma, and death if not identified and treated promptly. The advent of expanded newborn screening using tandem mass spectrometry has dramatically improved detection rates and outcomes for many of these conditions (Wilcken et al., 2003; Therrell et al., 2014).

This review provides a thorough examination of amino acid biochemistry, the major inborn errors affecting amino acid pathways, the molecular and cellular mechanisms of toxicity, clinical presentations, diagnostic approaches, and current and emerging therapeutic strategies. The objective is to serve as a comprehensive reference for clinicians, biochemists, students, and researchers working in the field of metabolic medicine.

2. BIOCHEMISTRY OF AMINO ACIDS

2.1 Structure and General Properties

All standard amino acids share a common backbone consisting of a central alpha-carbon (Cα) bonded to four groups: an amino group ($-NH_2$), a carboxyl group (-COOH), a hydrogen atom, and a distinctive side chain (R group) that determines the identity and properties of each amino acid. At physiological pH (~7.4), the amino group exists as $-NH_3^+$ and the carboxyl group as $-COO^-$, making amino acids zwitterionic (dipolar ionic) molecules (Berg et al., 2015).

The R groups vary enormously in size, shape, charge, hydrogen-bonding capacity, and chemical reactivity. This structural diversity is what confers the remarkable variety of protein functions. With the exception of glycine, the Cα of all amino acids is a chiral center, and virtually all naturally occurring amino acids possess the L-configuration, which corresponds to the S configuration by the Cahn-Ingold-Prelog system (Nelson & Cox, 2021).

2.2 Classification of Amino Acids

Amino acids are classified by several criteria: by the polarity of their R groups (nonpolar, polar uncharged, positively charged, negatively charged), by their metabolic fate (glucogenic, ketogenic, or both), or by nutritional essentiality (essential, non-essential, conditionally essential).

Essential Amino Acids: Nine amino acids cannot be synthesized by humans in adequate amounts and must be obtained from the diet: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Leucine, isoleucine, and valine are collectively termed

branched-chain amino acids (BCAAs) due to their aliphatic side-chain branching.

Non-Essential Amino Acids: These include alanine, asparagine, aspartate, glutamate, and serine, which are synthesized in sufficient quantities from glycolytic and TCA cycle intermediates.

Conditionally Essential Amino Acids: Arginine, cysteine, glutamine, glycine, proline, and tyrosine become essential under certain physiological or pathological conditions such as prematurity, illness, or specific metabolic defects (e.g., tyrosine becomes essential in PKU patients).

Category	Examples	Side Chain Property	Metabolic Fate
Nonpolar Aliphatic	Gly, Ala, Val, Leu, Ile, Pro, Met	Hydrophobic	Glucogenic / Ketogenic
Aromatic	Phe, Tyr, Trp	Hydrophobic / Amphipathic	Both
Polar Uncharged	Ser, Thr, Cys, Asn, Gln	H-bond donor/acceptor	Glucogenic
Positively Charged	Lys, Arg, His	Basic	Glucogenic
Negatively Charged	Asp, Glu	Acidic	Glucogenic

Table 1: Classification of Standard Amino Acids

2.3 General Pathways of Amino Acid Metabolism

Amino acids enter metabolic pathways primarily through transamination and oxidative deamination, which remove the amino group and yield the corresponding alpha-keto acid. Transamination is catalyzed by aminotransferases (transaminases) that transfer the amino group to alpha-ketoglutarate, producing glutamate and the cognate alpha-keto acid. Glutamate then undergoes oxidative deamination catalyzed by glutamate dehydrogenase in the mitochondria, liberating free ammonia (NH_4^+) and regenerating alpha-ketoglutarate (Brosnan, 2000).

The liberated ammonia is highly toxic and must be rapidly detoxified. In the liver, the urea cycle converts ammonia into urea, which is excreted by the kidneys. The carbon skeletons of amino acids—the alpha-keto acids produced after deamination—enter the TCA cycle as acetyl-CoA, pyruvate, alpha-ketoglutarate, succinyl-CoA, fumarate, or oxaloacetate, allowing for complete oxidation or gluconeogenesis (Newsholme & Leech, 2009).

3. THE UREA CYCLE: CENTRAL HUB OF NITROGEN METABOLISM

3.1 Overview and Enzymatic Steps

The urea cycle (also known as the ornithine cycle) is the primary mechanism for disposal of excess nitrogen generated from amino acid catabolism. It operates primarily in hepatocytes, with some enzymes present in the intestinal mucosa. The cycle was elucidated by Hans Krebs and Kurt Henseleit in 1932. Five enzymes catalyze the sequential reactions of the cycle (Brusilow & Horwich, 2001):

- **Step 1** — Carbamoyl phosphate synthetase I (CPS1): In the mitochondrial matrix, NH_4^+ and CO_2 combine with 2 ATP to form carbamoyl phosphate. This step is allosterically activated by N-acetylglutamate (NAG), synthesized by N-acetylglutamate synthase (NAGS) from glutamate and acetyl-CoA.
- **Step 2** — Ornithine transcarbamylase (OTC): Carbamoyl phosphate condenses with ornithine to form citrulline, which is then exported to the cytoplasm.
- **Step 3** — Argininosuccinate synthetase (ASS1): Citrulline combines with aspartate (the second nitrogen donor) in an ATP-dependent reaction to form argininosuccinate.
- **Step 4** — Argininosuccinate lyase (ASL): Argininosuccinate is cleaved to arginine and fumarate.
- **Step 5** — Arginase 1 (ARG1): Arginine is hydrolyzed to urea and ornithine, completing the cycle.

The fumarate produced enters the TCA cycle, linking nitrogen disposal with energy metabolism. One molecule of urea incorporates two nitrogen atoms—one from NH_4^+ (via carbamoyl phosphate) and one from aspartate. The overall reaction consumes 3 ATP per urea molecule synthesized, reflecting the metabolic investment required for nitrogen detoxification (Morris, 2002).

3.2 Regulation of the Urea Cycle

The urea cycle is regulated primarily by substrate availability and allosteric control. NAG is an obligatory activator of CPS1 and is synthesized in proportion to arginine availability, creating a positive feedback loop during high protein intake. Hormonal regulation also occurs: glucocorticoids upregulate urea cycle enzyme expression, consistent with increased protein catabolism during stress (Brusilow & Horwich, 2001). Long-term regulation involves transcriptional control of urea cycle genes in response to dietary protein content.

4. MAJOR INBORN ERRORS OF AMINO ACID METABOLISM

4.1 Phenylketonuria (PKU)

4.1.1 Biochemical Basis and Mechanism

Phenylketonuria (OMIM #261600) is the most common inborn error of amino acid metabolism in Caucasian populations, with an incidence of approximately 1 in 10,000–15,000 live

births in European populations. It is caused by mutations in the phenylalanine hydroxylase (PAH) gene located on chromosome 12q23.2, leading to deficient conversion of phenylalanine (Phe) to tyrosine (Tyr) (Blau et al., 2010).

Under normal circumstances, dietary phenylalanine is hydroxylated to tyrosine by phenylalanine hydroxylase (PAH), a hepatic enzyme that requires tetrahydrobiopterin (BH4) as a cofactor. BH4 is regenerated from dihydrobiopterin (BH2) by dihydropteridine reductase (DHPR). In PAH deficiency, phenylalanine accumulates in plasma and tissues and is shunted to alternative pathways, producing phenylpyruvate (via transamination), phenylacetate, and phenyllactate—collectively termed 'phenylketones' that appear in urine (Scriver et al., 2001).

Biochemical Pathway in PKU:

Phenylalanine → [PAH + BH4] → Tyrosine (BLOCKED IN PKU)

Phenylalanine → [aminotransferases] → Phenylpyruvate → Phenylacetate + Phenyllactate (ALTERNATIVE PATHWAY)

The neurotoxicity of PKU results from multiple mechanisms: (1) high phenylalanine competitively inhibits large neutral amino acid transporters (LAT1) at the blood-brain barrier, reducing brain uptake of other amino acids (Tyr, Trp, BCAAs); (2) decreased tyrosine impairs synthesis of dopamine, norepinephrine, and melanin; (3) reduced tryptophan decreases serotonin synthesis; and (4) direct inhibitory effects of phenylalanine metabolites on myelination (de Groot et al., 2010).

4.1.2 Clinical Features

Untreated PKU presents with progressive intellectual disability (IQ typically below 50 if untreated), seizures, behavioral problems, eczema, mousy body odor from phenylacetate, and hypopigmentation of hair, skin, and irises (from tyrosine deficiency impairing melanin synthesis). Maternal PKU (elevated Phe during pregnancy in affected mothers) causes microcephaly, congenital heart disease, and intellectual disability in the offspring regardless of the child's own PAH genotype (Koch et al., 2003).

4.1.3 Treatment

The primary treatment is dietary restriction of phenylalanine combined with Phe-free amino acid supplementation. BH4 (sapropterin dihydrochloride, Kuvan®) is effective in a subset of patients with BH4-responsive mutations, typically missense variants that result in misfolded but functional enzyme that can be stabilized by the cofactor. Pegvaliase (PEGylated phenylalanine ammonia lyase), an enzyme substitution therapy, was FDA-approved in 2018 and provides an alternative metabolic route for Phe degradation (Blau et al., 2016). Gene therapy approaches using adeno-associated viral vectors (AAV) are under clinical investigation.

4.2 Maple Syrup Urine Disease (MSUD)

4.2.1 Biochemical Basis

Maple syrup urine disease (OMIM #248600), also called branched-chain ketoaciduria, has an incidence of ~1 in 185,000 worldwide but is more prevalent in specific populations such as Old Order Mennonites (1 in 380). It results from deficiency of the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex, a mitochondrial multi-enzyme complex analogous to pyruvate dehydrogenase (Chuang & Shih, 2001).

The BCKDH complex catalyzes the irreversible oxidative decarboxylation of branched-chain alpha-keto acids (BCKAs) derived from the three BCAAs—leucine, isoleucine, and valine. The complex consists of four components encoded by separate genes: E1α (BCKDHA), E1β (BCKDHB), E2 (DBT), and E3 (DLD). Mutations in any of these subunit genes cause MSUD.

Pathway in MSUD:

Leucine → α-ketoisocaproate (KIC) → [BCKDH, BLOCKED] → isovaleryl-CoA

Isoleucine → α-keto-β-methylvalerate → [BCKDH, BLOCKED] → 2-methylbutyryl-CoA

Valine → α-ketoisovalerate (KIV) → [BCKDH, BLOCKED] → isobutyryl-CoA

Accumulation of leucine and its keto acid (KIC) is primarily responsible for the neurotoxicity seen in MSUD. Leucine competitively inhibits glutamate dehydrogenase, disrupts the TCA cycle, impairs energy metabolism, and causes cerebral edema through osmotic and metabolic mechanisms. Leucine also inhibits protein synthesis in neurons by competing with other large neutral amino acids for transport (Zinnanti et al., 2009).

4.2.2 Clinical Features and Treatment

Classic MSUD presents in the newborn period (days 3–5 of life) with poor feeding, vomiting, lethargy, a characteristic sweet/maple syrup odor to urine and cerumen, and rapidly progressive encephalopathy with opisthotonus, seizures, and coma. Without treatment, death occurs within weeks. MRI shows characteristic restricted diffusion in the myelin-rich areas of the basal ganglia, cerebral peduncles, and deep cerebellar white matter (Muelly et al., 2013).

Treatment requires immediate institution of a BCAA-restricted formula and, in acute metabolic crises, high-caloric enteral or parenteral nutrition to suppress catabolism. Liver transplantation effectively cures the metabolic phenotype by providing sufficient BCKDH enzyme activity. Thiamine (vitamin B1) supplementation helps a small subset with thiamine-responsive MSUD. Insulin is used in acute management to promote anabolism and BCAA utilization (Strauss et al., 2020).

4.3 Homocystinuria

4.3.1 Biochemistry and Pathogenesis

Classical homocystinuria (OMIM #236200) is caused by deficiency of cystathionine beta-synthase (CBS), the pyridoxal-5'-phosphate (PLP)-dependent enzyme that condenses homocysteine with serine to form cystathionine in the transsulfuration pathway. Incidence varies from 1:58,000 to 1:900,000 depending on population and diagnostic criteria (Mudd et al., 2001).

In CBS deficiency, homocysteine accumulates and

methionine levels rise (due to remethylation being the only alternative pathway), while cysteine becomes deficient. Elevated homocysteine undergoes auto-oxidation to homocystine (the disulfide form), which is excreted in urine (homocystinuria). Homocysteine causes vascular damage by: (1) endothelial dysfunction via oxidative stress and reduced NO bioavailability; (2) activation of coagulation and platelet aggregation; (3) interference with cross-linking of collagen and fibrillin in connective tissue (Finkelstein, 1998).

Methionine Cycle and Transsulfuration:

Methionine → S-adenosylmethionine (SAM) → S-adenosylhomocysteine (SAH) → Homocysteine

Homocysteine + Serine → [CBS] → Cystathionine → Cysteine + α-ketobutyrate (BLOCKED IN CBS DEFICIENCY)

Homocysteine → [Methionine synthase + B12 + MTHFR] → Methionine (REMETHYLATION)

4.3.2 Clinical Manifestations

The clinical tetrad of classical homocystinuria consists of: (1) ectopia lentis (lens dislocation, typically downward and inward, unlike Marfan syndrome where it is upward); (2) skeletal abnormalities including tall stature, arachnodactyly, kyphoscoliosis, osteoporosis, and pectus deformities; (3) thromboembolic events (stroke, pulmonary embolism, deep vein thrombosis, myocardial infarction) that are the leading cause of morbidity and mortality; and (4) intellectual disability and psychiatric manifestations (Mudd et al., 2001).

4.3.3 Treatment

About half of CBS-deficient patients are responsive to high-dose pyridoxine (vitamin B6), which stabilizes residual CBS enzyme. Non-responsive patients require methionine-restricted diet supplemented with cystine, betaine (which promotes remethylation of homocysteine), folic acid, and B12. Antiplatelet therapy and anticoagulation reduce thrombotic events. Novel therapies include mRNA therapy and enzyme replacement strategies under investigation (Majtan et al., 2018).

4.4 Tyrosinemia

4.4.1 Types and Biochemical Defects

Tyrosinemias are a group of disorders arising from defects in the tyrosine catabolic pathway. The three main types are:

Tyrosinemia Type I (Hepatorenal, OMIM #276700): Caused by deficiency of fumarylacetoacetate hydrolase (FAH), the terminal enzyme in tyrosine catabolism. This leads to accumulation of fumarylacetoacetate and maleylacetoacetate, which spontaneously cyclize to succinylacetoacetate and succinylacetone. Succinylacetone potently inhibits the heme biosynthetic enzyme delta-aminolevulinic acid dehydratase (ALAD), causing porphyria-like crises, and also inhibits the maleylacetoacetate isomerase step. It is hepatotoxic and carcinogenic, causing hepatocellular carcinoma at high rates if untreated (Mitchell et al., 2001).

Tyrosinemia Type II (Richner-Hanhart Syndrome, OMIM #276600): Due to deficiency of tyrosine aminotransferase (TAT), accumulation of tyrosine causes corneal deposits (crystalline keratopathy), painful palmoplantar hyperkeratosis, and in some cases intellectual disability. Treatment with tyrosine and phenylalanine restriction is effective.

Tyrosinemia Type III (OMIM #276710): Due to 4-hydroxyphenylpyruvate dioxygenase (HPPD) deficiency, it is the rarest form and presents with mild neurological symptoms.

4.4.2 Treatment of Type I Tyrosinemia

The introduction of nitisinone (NTBC, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione), an inhibitor of HPPD that blocks the production of toxic intermediates upstream of FAH, has revolutionized the management of Type I tyrosinemia. NTBC combined with a low-tyrosine/phenylalanine diet normalizes liver and kidney function and dramatically reduces the risk of hepatocellular carcinoma. Liver transplantation remains curative and is indicated when HCC is detected or when NTBC response is suboptimal (Lindstedt et al., 1992; van Ginkel et al., 2019).

4.5 Urea Cycle Disorders (UCDs)

4.5.1 Overview and Classification

Urea cycle disorders (UCDs) result from deficiency of any of the six enzymes or two transporters of the urea cycle. They are collectively the most common group of inborn errors of nitrogen metabolism, with a combined incidence of approximately 1 in 35,000 live births (Summar & Tuchman, 2001). The key UCDs are:

Disorder	Deficient Enzyme / Gene	Inheritance	Key Feature
NAGS deficiency	NAGS	AR	Hyperammonemia; N-carbamoylglutamate responsive
CPS1 deficiency	CPS1	AR	Severe neonatal hyperammonemia
OTC deficiency	OTC (Xp21.1)	X-linked	Most common UCD; variable in females
Citrullinemia Type I	ASS1	AR	Elevated citrulline; neonatal or adult onset

Argininosuccinic aciduria	ASL	AR	Elevated argininosuccinate; liver fibrosis
Arginase deficiency	ARG1	AR	Spastic diplegia; hyperargininemia

Table 2: Classification of Urea Cycle Disorders

4.5.2 Pathophysiology of Hyperammonemia

Ammonia (NH_3 / NH_4^+) is the primary toxic species in UCDs. At physiological pH, ammonia exists predominantly as ammonium ion (NH_4^+), but the lipid-soluble free ammonia form (NH_3) readily crosses the blood-brain barrier. In astrocytes, elevated ammonia is metabolized by glutamine synthetase, converting glutamate + NH_3 to glutamine, causing: (1) osmotic swelling of astrocytes (cerebral edema); (2) depletion of glutamate, an excitatory neurotransmitter; (3) inhibition of the TCA cycle via depletion of alpha-ketoglutarate; and (4) generation of reactive oxygen and nitrogen species (ROS/RNS) (Butterworth, 2002).

Clinically, acute hyperammonemia presents with vomiting, lethargy, progressive encephalopathy, cerebral edema, coma, and death if untreated. Plasma ammonia levels above 200 µmol/L (normal: <35 µmol/L) require immediate intervention.

4.5.3 Treatment of UCDs

Management of hyperammonemia in UCDs involves: (1) dietary protein restriction (reduced nitrogen load); (2) nitrogen scavenger drugs—sodium benzoate (conjugates glycine to hippurate, eliminating one nitrogen per molecule) and sodium phenylbutyrate/phenylacetate (conjugates glutamine to phenylacetylglutamine, eliminating two nitrogens per molecule); (3) arginine or citrulline supplementation to maintain the urea cycle flux in partial defects; (4) hemodialysis in severe acute crises; and (5) liver transplantation, which provides curative enzyme replacement (Summar et al., 2013).

Glycerol phenylbutyrate (Ravicti®) is a prodrug of sodium phenylbutyrate with superior palatability and safety profile. Carglumic acid (N-carbamoylglutamate, an NAG analogue) effectively activates CPS1 and is life-saving in NAGS deficiency (Häberle et al., 2012). Gene therapy trials using AAV8 vectors for OTC deficiency and other UCDs are in advanced stages of clinical development.

4.6 Organic Acidemias

4.6.1 Propionic Acidemia

Propionic acidemia (PA, OMIM #606054) results from deficiency of propionyl-CoA carboxylase (PCC), a biotin-dependent mitochondrial enzyme that converts propionyl-CoA to methylmalonyl-CoA. Propionyl-CoA derives from catabolism of the BCAAs valine and isoleucine, odd-chain fatty acids, methionine, threonine, and cholesterol. The PCC holoenzyme consists of alpha (PCCA) and beta (PCCB) subunits encoded on chromosomes 13 and 3 respectively (Desviat et al., 2004).

Accumulation of propionyl-CoA inhibits multiple mitochondrial enzymes including pyruvate carboxylase (causing secondary hypoglycemia), succinyl-CoA synthetase (impairing TCA cycle flux), and the electron transport chain (causing lactic acidosis and oxidative stress). Propionic acid also inhibits the urea cycle, resulting in secondary hyperammonemia. Propionyl-CoA inhibits N-acetylglutamate synthase (NAGS), reducing NAG levels and thereby impairing CPS1 activity (Cheema-Dhadli et al., 1975).

4.6.2 Methylmalonic Acidemia (MMA)

Methylmalonic acidemia (OMIM #251000) arises from deficiency of methylmalonyl-CoA mutase (MUT), a cobalamin (vitamin B12)-dependent enzyme that converts L-methylmalonyl-CoA to succinyl-CoA, connecting odd-chain amino acid catabolism to the TCA cycle. Additional causes include defects in adenosylcobalamin synthesis (cblA, cblB disorders) and combined adenosylcobalamin/methylcobalamin defects (cblC, cblD, cblF). Succinyl-CoA and TCA cycle intermediates become depleted while methylmalonic acid accumulates to nephrotoxic and neurotoxic levels (Manoli & Venditti, 2022).

MMA patients suffer from metabolic acidosis, hyperammonemia, neutropenia, thrombocytopenia, and progressive renal failure. Methylmalonic acid is a potent mitochondrial toxin that inhibits complex II and IV of the respiratory chain, impairs the TCA cycle, and causes mitochondrial ultrastructural damage particularly in renal tubular cells and neurons. Long-term complications include chronic kidney disease, optic nerve atrophy, stroke-like episodes affecting the basal ganglia, and pancreatitis (Manoli & Venditti, 2022).

4.6.3 Isovaleric Acidemia (IVA)

Isovaleric acidemia (OMIM #243500) results from deficiency of isovaleryl-CoA dehydrogenase (IVD), the first FAD-dependent step in leucine catabolism, leading to accumulation of isovaleric acid and its conjugates (isovalerylcarnitine, isovalerylglycine). The characteristic 'sweaty feet' odor is from isovaleric acid. Carnitine supplementation facilitates excretion of isovalerylcarnitine and is a cornerstone of management alongside leucine restriction (Tanaka et al., 1966; Ensenauer et al., 2004).

4.7 Disorders of Sulfur Amino Acid Metabolism

4.7.1 Cystinuria

Cystinuria (OMIM #220100) is a renal transport disorder caused by mutations in SLC3A1 (type A) or SLC7A9 (type B), encoding subunits of the cystine/dibasic amino acid transporter at the renal proximal tubule and intestinal brush border. It is not an amino acid degradation defect but a transport defect, resulting in excessive urinary excretion of cystine (and the dibasic amino acids lysine, arginine, and ornithine). Since cystine is poorly soluble at urinary pH (<6.5),

it precipitates to form urinary stones (Dello Strologo et al., 2002).

Cystinuria is the most common genetic cause of recurrent nephrolithiasis in children. Treatment involves high fluid intake to dilute urine, urinary alkalinization with potassium citrate, and D-penicillamine or tiopronin (which form soluble mixed disulfides with cysteine via thiol exchange, preventing cystine crystallization).

4.7.2 Cystinosis

Cystinosis (OMIM #219800) is an entirely different condition—a lysosomal storage disorder caused by mutations in CTNS, encoding the lysosomal cystine transporter (cystinosin). Cystine (the oxidized dimer) cannot exit lysosomes and accumulates within them as crystals, causing progressive cellular damage in virtually all tissues: Fanconi syndrome (proximal renal tubular dysfunction) in the first year, ESRD by the first decade, and later involvement of thyroid, muscle, eyes (characteristic corneal cystine crystals), and CNS. Cysteamine depletes lysosomal cystine via a novel mechanism: it enters lysosomes, reacts with cystine to form cysteamine-cysteine mixed disulfide, which exits via the lysine transporter PQLC2 (Gahl et al., 2002; Kalatzis et al., 2001).

4.8 Non-Ketotic Hyperglycinemia (NKH)

Non-ketotic hyperglycinemia (OMIM #605899), also termed glycine encephalopathy, is caused by deficiency of the glycine cleavage system (GCS), a four-protein mitochondrial complex (P-, H-, T-, and L-proteins) that catalyzes the oxidative decarboxylation of glycine and transfers the alpha-carbon to tetrahydrofolate. The most commonly mutated gene is GLDC (P-protein), followed by AMT (T-protein) (Kikuchi et al., 2008).

Glycine is a major inhibitory neurotransmitter in the brainstem and spinal cord (acting via strychnine-sensitive glycine receptors) and also serves as a co-agonist of NMDA glutamate receptors. In NKH, glycine accumulation in the CNS causes: (1) excessive inhibition at glycinergic synapses (hypotonia, apnea, hiccups); and (2) paradoxical NMDA receptor overactivation (seizures, excitotoxicity) due to elevated glycine at the NMDA co-agonist site. The clinical presentation includes neonatal hypotonia, apnea, intractable seizures (often with burst-suppression EEG), and profound intellectual disability (Applegarth & Toone, 2001).

5. DISORDERS OF AROMATIC AMINO ACID METABOLISM

5.1 Alkaptonuria

Alkaptonuria (OMIM #203500) holds historical significance as one of Garrod's original four inborn errors of metabolism. It is caused by deficiency of homogentisate 1,2-dioxygenase (HGD), an iron-containing enzyme in the tyrosine catabolic pathway that cleaves the aromatic ring of homogentisic acid (HGA). HGA accumulates and is excreted in urine, where it oxidizes and polymerizes to form a dark pigment (melanin-like benzoquinone acetic acid). This pigment also deposits in connective tissues, cartilage, heart valves, and sclera—a phenomenon termed ochronosis (La Du, 1998).

Clinically, alkaptonuria presents with darkening of urine upon standing (diagnostic clue in infancy), ochronosis causing grayish-blue pigmentation of ear cartilage and sclerae in adulthood, and severe ochronotic arthropathy of the spine and large joints mimicking ankylosing spondylitis. Nitisinone (used in tyrosinemia Type I) also reduces HGA production by blocking the upstream HPPD enzyme, and Phase 3 trials have demonstrated efficacy in slowing the rate of ochronosis progression (Ranganath et al., 2021).

5.2 Albinism

Oculocutaneous albinism (OCA) encompasses a group of disorders caused by defects in melanin biosynthesis from tyrosine in melanocytes. Type 1 OCA (OMIM #203100) is caused by mutations in TYR, encoding tyrosinase, the rate-limiting copper-containing enzyme that catalyzes the hydroxylation of tyrosine to DOPA and oxidation of DOPA to DOPAquinone in the melanin biosynthetic pathway. Other types involve mutations in OCA2, TYRP1, and SLC45A2. Clinical features include hypopigmentation of skin, hair, and eyes, photophobia, nystagmus, and significantly reduced visual acuity. Affected individuals have increased risk of skin cancers due to absent photoprotective melanin (Gronskov et al., 2007).

6. NEWBORN SCREENING FOR AMINO ACID DISORDERS

6.1 Historical Development and Methods

The concept of newborn screening was pioneered by Robert Guthrie in the 1960s, who developed a bacterial inhibition assay for phenylalanine detection using blood spotted on filter paper (Guthrie cards). This led to the identification of PKU before neurological damage occurred, demonstrating the principle that early detection enables effective treatment (Guthrie & Susi, 1963).

The introduction of tandem mass spectrometry (MS/MS) in the 1990s transformed newborn screening by enabling simultaneous quantification of dozens of amino acids, acylcarnitines, and other metabolites from a single dried blood spot. The RoHS/ACMG recommendations have expanded the uniform screening panel to include over 30 core conditions and 26 secondary targets, including most aminoacidopathies, organic acidemias, and fatty acid oxidation disorders (Therrell et al., 2014; American College of Medical Genetics & Genomics, 2006).

6.2 The MS/MS Platform

In tandem MS/MS newborn screening, dried blood spot extracts are analyzed by electrospray ionization (ESI) coupled to a triple quadrupole mass spectrometer. The first quadrupole selects precursor ions by mass-to-charge ratio (m/z), the second (collision cell) fragments ions using collision-induced dissociation (CID), and the third quadrupole detects characteristic product ions. Amino acids are measured as butyl ester derivatives (after butanolysis) using neutral loss scans or precursor-ion scans specific for each analyte class (Rashed et al., 1995).

The sensitivity and specificity of MS/MS screening have improved dramatically with introduction of stable-isotope-labeled internal standards for each metabolite, reducing both false-positive and false-negative rates. Second-tier molecular genetic testing is increasingly employed to confirm biochemical screen positives and reduce unnecessary parental anxiety from false positives (Chace et al., 2002).

7. PATHOPHYSIOLOGICAL MECHANISMS OF TOXICITY IN AMINOACIDOPATHIES

7.1 Excitotoxicity and Neuronal Death

Several amino acids and their metabolites act as excitotoxins by overstimulating glutamate receptors. Accumulation of quinolinate (from tryptophan catabolism), sulfite (in sulfite oxidase deficiency), and NMDA agonists causes neuronal calcium influx, mitochondrial dysfunction, ROS generation, and ultimately apoptosis via the intrinsic pathway involving cytochrome c release and caspase activation (Beal, 1998).

7.2 Mitochondrial Dysfunction

Organic acid accumulations in propionic, methylmalonic, and isovaleric acidemias inhibit multiple components of the mitochondrial respiratory chain (primarily Complex I and II) and the TCA cycle, causing energy failure, lactic acidosis, and generation of ROS that damage lipids, proteins, and mtDNA. This mitochondrial toxicity accounts for cardiomyopathy, basal ganglia injury (metabolic stroke), and progressive organ failure in these conditions (Manoli & Venditti, 2022; Schwab et al., 2006).

7.3 Epigenetic and One-Carbon Metabolism Effects

Disruption of the methionine cycle in homocystinuria and remethylation disorders affects S-adenosylmethionine (SAM) availability—the universal methyl donor for DNA methyltransferases (DNMT), histone methyltransferases, and other methyltransferase reactions. SAM depletion leads to global DNA hypomethylation and aberrant gene expression, contributing to the developmental and neurological sequelae beyond direct homocysteine toxicity (Stover & Garza, 2002).

7.4 Protein Aggregation and ER Stress

In many IEM, misfolded mutant proteins accumulate in the endoplasmic reticulum, triggering the unfolded protein response (UPR). Sustained ER stress activates downstream apoptotic pathways (CHOP/DDIT3) and impairs proteasomal degradation. This mechanism underlies cell death in some forms of PKU, lysosomal storage disorders, and alpha-1-antitrypsin deficiency. Pharmacological chaperones exploit this by stabilizing mutant proteins and reducing ER stress (Guerreiro et al., 2022).

8. DIAGNOSTIC APPROACHES

8.1 Plasma Amino Acid Analysis

Quantitative plasma amino acid analysis by ion-exchange chromatography (IEC) with ninhydrin post-column derivatization, or by reverse-phase HPLC or LC-MS/MS with pre-column derivatization, provides the definitive biochemical diagnosis of most aminoacidopathies. Results are interpreted against age-specific reference ranges, as many amino acids have physiologically different concentrations in neonates compared to older children and adults (Blau et al., 2014).

8.2 Urine Organic Acid Analysis

Gas chromatography-mass spectrometry (GC-MS) analysis of urine organic acids is essential for diagnosing organic acidemias (MMA, PA, IVA), OAT deficiency, and secondary markers of other conditions. Characteristic organic acid profiles enable specific diagnosis: methylmalonate and methylcitrate in MMA; 3-hydroxypropionate, propionylglycine, and methylcitrate in PA; isovalerylglycine and 3-hydroxyisovalerate in IVA (Engelke et al., 2022).

8.3 Acylcarnitine Analysis

Plasma acylcarnitine profiling by ESI-MS/MS or LC-MS/MS is a powerful diagnostic tool for fatty acid oxidation disorders and organic acidemias. Characteristic acylcarnitine species accumulate in specific disorders: C3 (propionylcarnitine) in PA and MMA; C5 (isovalerylcarnitine) in IVA; C5:1 in MSUD. Carnitine supplementation is indicated when secondary carnitine depletion (from acylcarnitine excretion) occurs (Millington et al., 1990).

8.4 Molecular Genetic Testing

Next-generation sequencing (NGS)—including gene panels, whole exome sequencing (WES), and whole genome sequencing (WGS)—is now routinely used to confirm biochemical diagnoses, identify specific mutations for genotype-phenotype correlation and prognosis, enable targeted family testing, and identify pathogenic variants in atypical or biochemically mild presentations. For X-linked OTC deficiency, molecular diagnosis in females (who may be symptomatic or asymptomatic carriers) is particularly important for management and genetic counseling (Ah Mew et al., 2019).

9. THERAPEUTIC STRATEGIES

9.1 Dietary Management

Dietary therapy remains the cornerstone of treatment for most aminoacidopathies and organic acidemias. The principles include: (1) restriction of the offending amino acid(s) to the minimum necessary for normal growth; (2) supplementation with amino acid formulas lacking the restricted amino acid to ensure adequate protein synthesis; (3) supplementation of amino acids that become conditionally essential (e.g., tyrosine and cysteine in PKU); and (4) high-caloric support during catabolic crises to suppress endogenous protein catabolism (van Wegberg et al., 2017).

Adherence to metabolic diets is lifelong and challenging due to palatability issues, expense, and social impacts. Large neutral amino acid (LNAA) supplementation has been used as an adjunct in PKU to competitively reduce phenylalanine uptake at the blood-brain barrier. Glycomacropeptide (GMP)-based foods offer an alternative protein source in PKU with naturally low phenylalanine content and improved palatability (van Wegberg et al., 2017).

9.2 Pharmacological Cofactor Therapy

Several IEM respond to pharmacological doses of cofactor vitamins that serve as substrates or cofactors for the deficient enzyme: BH4 (sapropterin) in PKU and some BH4 synthesis/recycling disorders; pyridoxine (B6) in CBS-responsive homocystinuria; thiamine (B1) in thiamine-responsive MSUD and pyruvate dehydrogenase deficiency; riboflavin (B2) in multiple acyl-CoA dehydrogenase deficiency (MADD/GA2); cobalamin (B12) in methylmalonyl-CoA mutase deficiency and cbl disorders; and biotin in biotinidase deficiency and propionic acidemia (Mayatepek, 2019).

9.3 Enzyme Replacement Therapy (ERT)

ERT involves administration of recombinant enzyme to compensate for the endogenous deficiency. Pegvaliase (Palynziq®), a PEGylated phenylalanine ammonia lyase from Anabaena variabilis, degrades phenylalanine to trans-cinnamic acid and ammonia via a non-mammalian route and is FDA-approved for adults with uncontrolled PKU. For lysosomal storage disorders involving amino acid-related pathways (e.g., cystinosis managed with cysteamine rather than enzyme), specific ERT is not available. Challenges of ERT include immunogenicity, need for parenteral administration, and failure to reach the CNS (Blau et al., 2016).

9.4 Substrate Reduction Therapy

Nitisinone (NTBC) in tyrosinemia Type I represents the paradigm of substrate reduction therapy—blocking an upstream enzyme to prevent production of downstream toxic metabolites. Similar strategies are being explored for other IEM. In Gaucher disease (a related metabolic disorder), eliglustat inhibits glucosylceramide synthase. The approach is conceptually applicable to many IEM where an upstream block can reduce toxic substrate accumulation without excessively depleting essential products (Lindstedt et al., 1992).

9.5 mRNA Therapy

Systemic delivery of mRNA encoding the deficient enzyme, encapsulated in lipid nanoparticles (LNPs), enables transient protein replacement. mRNA-based therapy for PA (PCCA mRNA-LNP), MMA (MUT mRNA-LNP), and OTC deficiency (OTC mRNA-LNP) are in preclinical and Phase 1/2 clinical development. The hepatotropism of LNPs makes this approach particularly suitable for liver-based IEM. Unlike gene therapy, mRNA therapy does not integrate into the genome and requires repeated administration, but carries no mutagenesis risk (Jiang et al., 2020).

9.6 Gene Therapy

Gene therapy aims to provide a functional copy of the deficient gene using viral vectors (predominantly AAV serotypes 2, 5, 8, and 9) or non-viral delivery systems. AAV8-mediated OTC gene transfer has shown proof-of-concept in clinical trials. AAV-PAH for PKU is in Phase 3 trials. Challenges include limited vector capacity for large genes, pre-existing neutralizing antibodies against AAV capsids, risk of insertional mutagenesis with integrating vectors, and potential immune responses to the transgene product (Brunetti-Pierri, 2021).

Advancements in in vivo CRISPR-Cas9 gene editing hold promise for permanent correction of point mutations underlying IEM, with LNP-delivered CRISPR components achieving efficient hepatic editing in preclinical models. Base editing and prime editing offer higher precision with reduced off-target effects and no requirement for double-strand breaks (Liu et al., 2019).

9.7 Liver and Organ Transplantation

Liver transplantation (LT) provides definitive enzymatic correction for hepatic IEM including UCD, PA, MMA, Type I tyrosinemia, and MSUD. However, LT does not correct extrahepatic manifestations (e.g., renal involvement in MMA, neurological complications already established). Split liver, living-related donor, and domino transplantation strategies have expanded donor availability. Combined liver-kidney transplantation is increasingly performed in MMA patients with end-stage renal disease (Shchelochkov et al., 2016).

10. EMERGING THERAPIES AND FUTURE DIRECTIONS

The landscape of IEM therapy is rapidly evolving. Several emerging strategies merit discussion:

Microbiome Modulation: Gut bacteria contribute significantly to amino acid metabolism. Probiotic supplementation with bacteria expressing phenylalanine ammonia lyase (PAL) or ammonia-consuming organisms is being explored for PKU and UCDs. Genetically engineered bacteria (e.g., SYNB1618 for PKU, SYNB1020 for hyperammonemia) that metabolize excess substrate in the gut represent a novel 'living drug' platform in Phase 2 trials (Isabella et al., 2018).

Induced Pluripotent Stem Cell (iPSC) Therapy: Patient-derived iPSCs corrected ex vivo using gene editing and differentiated into hepatocytes offer the prospect of autologous cell replacement without immunosuppression, avoiding alloimmune risks of liver transplantation (Fattahi et al., 2016).

Pharmacological Chaperones: Small molecules that bind to and stabilize misfolded mutant enzymes can rescue residual enzyme activity in many IEM. This approach is best exemplified by sapropterin in BH4-responsive PKU and eliglustat/miglustat in Gaucher disease, and is being pursued for MMA, PA, and other organic acidemias (Guerreiro et al., 2022).

Antisense Oligonucleotides (ASOs): ASOs can modulate gene expression by blocking mRNA translation or altering splicing. For gain-of-function mutations or disorders with toxic metabolite production, ASOs targeting upstream enzymes (analogous to nitisinone's pharmacological mechanism) represent a viable precision approach (Crooke et al., 2021).

11. GENETIC COUNSELING AND PSYCHOSOCIAL CONSIDERATIONS

Most amino acid disorders follow autosomal recessive inheritance, meaning each sibling of an affected child carries a 25% recurrence risk. Exceptions include OTC deficiency (X-linked), and some conditions with X-linked or mitochondrial inheritance. Genetic counseling is an essential component of management, providing families with accurate information about recurrence risks, carrier testing, prenatal diagnosis (via chorionic villus sampling or amniocentesis for DNA analysis or enzyme assay), and preimplantation genetic testing (PGT) for couples pursuing IVF (Saudubray et al., 2016).

The psychosocial burden of IEM is substantial. Families face lifelong dietary restrictions that affect quality of life, social participation, and mental health of both patients and caregivers. Adolescence and the transition to adulthood are particularly challenging, with metabolic control often deteriorating. Psychological support, dietitian-led family education, peer support groups, and metabolic team-based multidisciplinary care are all essential components of comprehensive management (MacDonald et al., 2012).

12. SUMMARY AND CONCLUSIONS

Amino acids and their metabolic pathways occupy a central position in human biochemistry, and inborn errors affecting these pathways constitute a medically important group of genetic disorders that collectively cause significant morbidity and mortality worldwide. From the pioneering observations of Garrod through to the molecular era and beyond, our understanding of these conditions has grown exponentially, enabling increasingly effective therapeutic interventions.

Phenylketonuria demonstrated that a metabolic disorder could be treated effectively through dietary intervention when identified early, establishing the paradigm for newborn screening programs. Subsequent decades have witnessed the application of MS/MS technology to expand screening to dozens of conditions simultaneously, saving countless lives. The development of sapropterin for PKU, nitisinone for tyrosinemia, and nitrogen scavenger drugs for UCDs exemplify the translation of biochemical understanding into therapeutic innovation.

Looking ahead, gene therapy, mRNA therapy, pharmacological chaperones, and engineered microbiome organisms offer the prospect of truly curative or near-curative treatments for conditions that currently require demanding lifelong dietary therapy. Advances in newborn screening technology—including next-generation sequencing-based expanded screening—will further improve detection rates and enable earlier, more targeted intervention.

For clinicians and researchers alike, a deep understanding of amino acid biochemistry and the inborn errors that disrupt it remains indispensable. As the molecular tools available to study and treat these conditions continue to advance, the outlook for patients with amino acid disorders has never been more promising.

13. REFERENCES

1. Ah Mew, N., Simpson, K. L., Garg, U., Bhardwaj, S. B., Chen, E. L., & Enns, G. M. (2019). Urea cycle disorders overview. In M. P. Adam, H. H. Ardinger, & R. A. Pagon (Eds.), GeneReviews® [Internet]. University of Washington.
2. American College of Medical Genetics and Genomics. (2006). Newborn screening: Toward a uniform screening panel and system—executive summary. Pediatrics, 117(5 Suppl), S296–S307.
3. Applegarth, D. A., & Toone, J. R. (2001). Nonketotic hyperglycinemia (glycine encephalopathy): Laboratory diagnosis. Molecular Genetics and Metabolism, 74(1–2), 139–146.
4. Beal, M. F. (1998). Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Annals of Neurology, 44(3 Suppl 1), S110–S114.
5. Berg, J. M., Tymoczko, J. L., Stryer, L., & Gatto, G. J. (2015). Biochemistry (8th ed.). W.H. Freeman and Company.
6. Blau, N., van Spronsen, F. J., & Levy, H. L. (2010). Phenylketonuria. The Lancet, 376(9750), 1417–1427.
7. Blau, N., Shen, N., & Carducci, C. (2014). Molecular genetics and diagnosis of phenylketonuria: State of the art. Expert Review of Molecular Diagnostics, 14(6), 655–671.
8. Blau, N., Burton, B. K., Phornphutkul, C., & Mitchell, J. J. (2016). Phenylketonuria and BH4 deficiencies. UNI-MED Science.
9. Brosnan, J. T. (2000). Glutamate, at the interface between amino acid and carbohydrate metabolism. Journal of Nutrition, 130(4S Suppl), 988S–990S.
10. Brunetti-Pierri, N. (2021). Gene therapy for inborn errors of liver metabolism. Journal of Inherited Metabolic Disease, 44(6), 1410–1418.
11. Brusilow, S. W., & Horwich, A. L. (2001). Urea cycle enzymes. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease (8th ed., pp. 1909–1963). McGraw-Hill.
12. Butterworth, R. F. (2002). Pathophysiology of hepatic encephalopathy: A new look at ammonia. Metabolic Brain Disease, 17(4), 221–227.
13. Chace, D. H., Kalas, T. A., & Naylor, E. W. (2002). The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annual Review of Genomics and Human Genetics, 3, 17–45.
14. Cheema-Dhadli, S., Leznoff, C. C., & Halperin, M. L. (1975). Effect of 2-methylcitrate on citrate metabolism: Implications for the management of patients with propionic acidemia and methylmalonic aciduria. Pediatric Research, 9(12), 905–908.
15. Chuang, D. T., & Shih, V. E. (2001). Maple syrup urine disease (branched-chain ketoaciduria). In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease (8th ed., pp. 1971–2005). McGraw-Hill.
16. Crooke, S. T., Liang, X. H., Baker, B. F., & Crooke, R. M. (2021). Antisense technology: A review. Journal of Biological Chemistry, 296, 100416.

17. de Groot, M. J., Hoeksma, M., Blau, N., Reijngoud, D. J., & van Spronsen, F. J. (2010). Pathogenesis of cognitive dysfunction in phenylketonuria: Review of hypotheses. Molecular Genetics and Metabolism, 99(Suppl 1), S86–S89.
18. Dello Strologo, L., Pras, E., Pontesilli, C., Beccia, E., Ricci-Barbini, V., de Sanctis, L., ... & Rizzoni, G. (2002). Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: A need for a new classification. Journal of the American Society of Nephrology, 13(10), 2547–2553.
19. Desviat, L. R., Pérez, B., Pérez-Cerdá, C., & Ugarte, M. (2004). Propionic acidemia: Mutation update and functional and structural effects of the variant alleles. Molecular Genetics and Metabolism, 83(1–2), 28–37.
20. Engelke, U. F. H., Van Gelder, C. M., Panis, B., De Vries, M. C., & Wevers, R. A. (2022). GC-MS in metabolic disorders. In F. Blau, M. Duran, M. Blaskovics, & K. M. Gibson (Eds.), Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases (pp. 745–760). Springer.
21. Ensenauer, R., Vockley, J., Willard, J. M., Huber, B. M., Baumgartner, M. R., & Liebl, B. (2004). A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. American Journal of Human Genetics, 75(6), 1136–1142.
22. Fattahi, F., Tan, Z. Y., Han, J., Ng, L. F., Ginhoux, F., Bhatt, D. L., ... & Bhatt, D. (2016). Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease. Nature, 531(7592), 105–109.
23. Fernandez-Tejada, M., Yépez, V. A., & Torres, L. M. (2022). Amino acid metabolism and related disorders. In Biochemistry of Metabolic Diseases (Chapter 3). Elsevier.
24. Finkelstein, J. D. (1998). The metabolism of homocysteine: Pathways and regulation. European Journal of Pediatrics, 157(Suppl 2), S40–S44.
25. Gahl, W. A., Thoene, J. G., & Schneider, J. A. (2002). Cystinosis. New England Journal of Medicine, 347(2), 111–121.
26. Garrod, A. E. (1909). Inborn errors of metabolism. Oxford University Press.
27. Gronskov, K., Ek, J., & Brondum-Nielsen, K. (2007). Oculocutaneous albinism. Orphanet Journal of Rare Diseases, 2, 43.
28. Guerreiro, G., Folda, A., Sondermann, H., & Clarke, L. A. (2022). Pharmacological chaperones in inherited metabolic disease: From bench to bedside. International Journal of Molecular Sciences, 23(12), 6595.
29. Guthrie, R., & Susi, A. (1963). A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics, 32, 338–343.
30. Häberle, J., Boddaert, N., Burlina, A., Chakrapani, A., Dixon, M., Huemer, M., ... & Rubio, V. (2012). Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet Journal of Rare Diseases, 7, 32.
31. Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., ... & Kotula, J. W. (2018). Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nature Biotechnology, 36(9), 857–864.
32. Jiang, L., Berraondo, P., Jericó, D., Guey, L. T., Sampedro, A., Frassetto, A., ... & Bhatt, D. L. (2020). Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nature Medicine, 24(12), 1899–1909.
33. Kalatzis, V., Cherqui, S., Antignac, C., & Gasnier, B. (2001). Cystinosin, the protein defective in cystinosis, is a H+-driven lysosomal cystine transporter. EMBO Journal, 20(21), 5940–5949.
34. Kikuchi, G., Motokawa, Y., Yoshida, T., & Hiraga, K. (2008). Glycine cleavage system: Reaction mechanism, physiological significance, and hyperglycinemia. Proceedings of the Japan Academy, Series B, 84(7), 246–263.
35. Koch, R., Hanley, W., Levy, H., Matalon, K., Matalon, R., Rouse, B., ... & Widaman, K. (2003). The maternal phenylketonuria international study: 1984–2002. Pediatrics, 112(6 Pt 2), 1523–1529.
36. La Du, B. N. (1998). Alkaptonuria. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease (7th ed., pp. 1371–1386). McGraw-Hill.
37. Lindstedt, S., Holme, E., Lock, E. A., Hjalmarson, O., & Strandvik, B. (1992). Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. The Lancet, 340(8823), 813–817.
38. Liu, D. R., Anzalone, A. V., & Koblan, L. W. (2019). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature, 575(7782), 464–469.
39. MacDonald, A., Rocha, J. C., van Rijn, M., & Feillet, F. (2012). Nutrition in phenylketonuria. Molecular Genetics and Metabolism, 104(Suppl), S10–S18.
40. Majtan, T., Krijt, J., Sokolova, J., Krizkova, M., Ralat, M. A., Kent, J., ... & Kraus, J. P. (2018). Biogenesis of hydrogen sulfide and thioethers by cystathionine beta-synthase. Antioxidants & Redox Signaling, 28(4), 311–323.
41. Manoli, I., & Venditti, C. P. (2022). Methylmalonic acidemia. In M. P. Adam, H. H. Ardinger, & R. A. Pagon (Eds.), GeneReviews® [Internet]. University of Washington.
42. Mayatepek, E. (2019). Inborn errors of metabolism: From bench to bedside. Springer.
43. Millington, D. S., Kodo, N., Norwood, D. L., & Roe, C. R. (1990). Tandem mass spectrometry: A new

method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. Journal of Inherited Metabolic Disease, 13(3), 321–324.
44. Mitchell, G. A., Grompe, M., Lambert, M., & Tanguay, R. M. (2001). Hypertyrosinemia. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease (8th ed., pp. 1777–1805). McGraw-Hill.
45. Morris, S. M. Jr. (2002). Regulation of enzymes of the urea cycle and arginine metabolism. Annual Review of Nutrition, 22, 87–105.
46. Mudd, S. H., Levy, H. L., & Krauss, J. P. (2001). Disorders of transsulfuration. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease (8th ed., pp. 2007–2056). McGraw-Hill.
47. Muelly, E. R., Moore, G. J., Bunce, S. C., Mack, J., Bigler, D. C., Morton, D. H., & Strauss, K. A. (2013). Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. Journal of Clinical Investigation, 123(4), 1809–1820.
48. Nelson, D. L., & Cox, M. M. (2021). Lehninger Principles of Biochemistry (8th ed.). W.H. Freeman and Company.
49. Newsholme, P., & Leech, A. R. (2009). Functional biochemistry in health and disease. Wiley-Blackwell.
50. Ranganath, L. R., Milan, A. M., Hughes, A. T., Dutton, J. J., Fitzgerald, R., Briggs, M. C., ... & Gallagher, J. A. (2021). Suitability of nitisinone in alkaptonuria: A 3-year update of the SONIA 2 study investigating the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Rheumatology, 60(11), 5302–5312.
51. Rashed, M. S., Ozand, P. T., Bucknall, M. P., & Little, D. (1995). Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatric Research, 38(3), 324–331.
52. Saudubray, J. M., Baumgartner, M., & Walter, J. (2016). Inborn Metabolic Diseases: Diagnosis and Treatment (6th ed.). Springer.
53. Schwab, M. A., Sauer, S. W., Okun, J. G., Nijtmans, L. G. J., Rodenburg, R. J. T., van den Heuvel, L. P., ... & Kölker, S. (2006). Secondary mitochondrial dysfunction in propionic aciduria: A pathogenic role for endogenous mitochondrial toxins. Biochemical Journal, 398(1), 107–112.
54. Scriver, C. R., Beaudet, A. L., Sly, W. S., & Valle, D. (Eds.). (2001). The Metabolic and Molecular Bases of Inherited Disease (8th ed.). McGraw-Hill.
55. Shchelochkov, O. A., Carrillo, N., & Venditti, C. (2016). Propionic acidemia. In M. P. Adam, H. H. Ardinger, & R. A. Pagon (Eds.), GeneReviews® [Internet]. University of Washington.
56. Stover, P. J., & Garza, C. (2002). Bringing individuality to public health recommendations. Journal of Nutrition, 132(8 Suppl), 2476S–2480S.
57. Strauss, K. A., Carson, V. J., Soltys, K., Young, M. E., Bowser, L. E., Puffenberger, E. G., & Morton, D. H. (2020). Branched-chain alpha-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes. Molecular Genetics and Metabolism, 129(3), 193–206.
58. Summar, M. L., & Tuchman, M. (2001). Proceedings of a consensus conference for the management of patients with urea cycle disorders. Journal of Pediatrics, 138(1 Suppl), S6–S10.
59. Summar, M. L., Dobbelaere, D., Brusilow, S., & Lee, B. (2013). Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multisite investigation. Amino Acids, 45(2), 353–358.
60. Tanaka, K., Budd, M. A., Efron, M. L., & Isselbacher, K. J. (1966). Isovaleric acidemia: A new genetic defect of leucine metabolism. Proceedings of the National Academy of Sciences USA, 56(1), 236–242.
61. Therrell, B. L., Padilla, C. D., Loeber, J. G., Kneisser, I., Saadallah, A., Borrajo, G. J., & Adams, J. (2014). Current status of newborn screening worldwide: 2015. Seminars in Perinatology, 39(3), 171–187.
62. van Ginkel, W. G., Jahja, R., Huijbregts, S. C. J., Daly, A., MacDonald, A., De Laet, C., ... & van Spronsen, F. J. (2019). Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet Journal of Rare Diseases, 11(1), 87.
63. van Wegberg, A. M. J., MacDonald, A., Ahring, K., Bélanger-Quintana, A., Blau, N., Bosch, A. M., ... & van Spronsen, F. J. (2017). The complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet Journal of Rare Diseases, 12(1), 162.
64. Wilcken, B., Wiley, V., Hammond, J., & Carpenter, K. (2003). Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England Journal of Medicine, 348(23), 2304–2312.
65. Zinnanti, W. J., Lazovic, J., Griffin, K., Skvorak, K. J., Paul, H. S., Homanics, G. E., ... & Flanagan, J. M. (2009). Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain, 132(4), 903–918.